Jiang, Shiyu
Qin, Yan
Gui, Lin
Liu, Peng
Jiang, Hongxin
Liu, Biao
Yang, Jianliang
Yang, Sheng
He, Xiaohui
Zhou, Shengyu
Du, Xinhua
Yi, Yuting
Lin, Jing
Shi, Yuankai http://orcid.org/0000-0002-8685-6744
Funding for this research was provided by:
National Key Technology Support Program (2014BAI09B12)
National New Drug Innovation Program (2017ZX09304015)
CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001)
Article History
First Online: 1 April 2020
Compliance with Ethical Standards
:
: This study was supported by the National Key Technology Support Program (2014BAI09B12), National New Drug Innovation Program (2017ZX09304015), Beijing-Tianjin-Hebei Cooperation Program for basic research under Grant H2018206591, and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1-001).
: Jing Lin is an employee of Burning Rock Biotech. Xinhua Du and Yuting Yi are employees of Geneplus-Beijing. Shiyu Jiang, Yan Qin, Lin Gui, Peng Liu, Hongxin Jiang, Biao Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, and Yuankai Shi declare that they have no conflicts of interest that might be relevant to the contents of this article.
: The study was approved by the Review Board of Cancer Institute and Hospital, Chinese Academy of Medical Sciences and conducted in accordance with the Declaration of Helsinki. Consent to publish was obtained from the participants for reporting individual patient data.